Splitomicin

5690-03-9

198.22

DMSO : 100 mg/mL (504.49 mM; Need ultrasonic)

Epigenetics; Cell Cycle/DNA Damage

Splitomicin (Splitomycin) is a selective Sir2p inhibitor. Splitomicin inhibits NAD⁺-dependent HDAC activity of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast extract with an IC₅₀ of 60 uM^[1]. In Vitro: Splitomicin (10-333 uM; 24 hours) elicits antiproliferative effects in MCF-7 and H1299 cells in a dose-dependent manner in colony formation assay. Splitomicin (33 uM) fails to decrease the number of colonies, but Splitomicin (100 and 333 uM) effectively inhibits colony formation in MCF-7 and H1299 cells^[2]. In Vivo: Splitomicin (80 mg/kg with an intraperitoneal injection every 24 h for 5 days, in mice) enhances tissue factor (TF) activity in the arterial vessel wall and accelerates carotid artery thrombus formation in a photochemical injury model^[3].